Capricor Therapeutics (CAPR) Enterprise Value (2016 - 2025)
Capricor Therapeutics (CAPR) has 15 years of Enterprise Value data on record, last reported at -$98.6 million in Q3 2025.
- For Q3 2025, Enterprise Value fell 15.92% year-over-year to -$98.6 million; the TTM value through Sep 2025 reached -$98.6 million, down 15.92%, while the annual FY2024 figure was -$151.5 million, 283.7% down from the prior year.
- Enterprise Value reached -$98.6 million in Q3 2025 per CAPR's latest filing, up from -$122.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$28.5 million in Q3 2023 and bottomed at -$151.5 million in Q4 2024.
- Average Enterprise Value over 5 years is -$61.9 million, with a median of -$41.9 million recorded in 2021.
- Peak YoY movement for Enterprise Value: soared 38.81% in 2023, then crashed 316.81% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$34.9 million in 2021, then decreased by 18.74% to -$41.4 million in 2022, then grew by 4.67% to -$39.5 million in 2023, then tumbled by 283.7% to -$151.5 million in 2024, then skyrocketed by 34.95% to -$98.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$98.6 million in Q3 2025, -$122.8 million in Q2 2025, and -$144.8 million in Q1 2025.